Herpes simplex

Microbix & BioGX Collaborate on real-time PCR Assays & Controls

Retrieved on: 
Thursday, December 7, 2023
Herpes simplex, Chickenpox, Mpox, OTCQX, Collection, Business, Applied Biosystems, PCR, Syphilis, Refrigeration, COVID, Business development, SARS-CoV-2, TSX, SVP, Pleasure, XFree86, Treponema pallidum

Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.

Key Points: 
  • Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform – a benchtop instrument with capabilities for syndromic testing.
  • Microbix QAPs are now referenced in BioGX Assay Product Inserts (available at https://www.biogx.com ), with additional QAPs to be referenced as the collaboration expands.
  • Xfree technology provides a complete lyophilized test in a single tube – using the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition in real-time PCR testing.
  • Phil Casselli, SVP of Sales & Business Development at Microbix, commented, “It has been a pleasure to work with Robert and his team at BioGX to support their customer base with robust External Quality Controls.

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Cue Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Health, Medical Devices, Telemedicine, Virtual Medicine, FDA, RSV, Herpes simplex, EBITDA, GAAP, PCR, De novo, COVID, COVID-19, Cue, EUA, Cassette tape, Pharmaceutical industry, Payment card, Video game, Bookkeeping, Microbiology Spectrum

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.

Key Points: 
  • Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.
  • I’m proud of the Cue team for the strong execution across all fronts.”
    Revenue was $17.5 million for the third quarter of 2023.
  • GAAP net loss in the third quarter of 2023 was $47.0 million and earnings per diluted share was a loss of $0.31, an improvement of $0.24 from the second quarter of 2023.
  • Cue ended the third quarter with cash of $111.5 million and the company continues to operate with no debt obligations.

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
Wednesday, October 25, 2023
Floater, Gland, Stomach, Glaucoma, Viral, Pressure, Health Canada, Dexamethasone, Disease, Risk, Ibuprofen, Allergy, Eye, Red, Nonsteroidal anti-inflammatory drug, Drug identification number, Tuberculosis, Fungal infection, Infection, Sale, Mouth, Burns, Throat, Health, Plasma protein binding, Aspirin, NPN, Rash, Iris cyst, Diabetes, Atrophoderma, Safety, Natural product, Patient, Nose, Prescription drug, Maharashtra University of Health Sciences, Asthma, Triamcinolone, DIN, Pregnancy, Retinal detachment, Pharmacy, Neostigmine, Xeroderma, Cataract, Tropical ulcer, Blurred vision, Herpes simplex, Itch, Skin, Absorption, Inflammation, Common, Hair, NSAID, Myasthenia gravis, Swelling, Weakness, Elasticity, Failure, Dietary supplement, Cosmetics

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Public advisory - Unauthorized health products seized from Yang Sheng Health Food and G&R Ginseng Trading stores in Richmond, B.C., may pose serious health risks

Retrieved on: 
Friday, August 11, 2023
Elasticity, Hair, Prescription drug, Gland, Atrophoderma, Tenderness, Rash, Plasma protein binding, Nose, Ketoconazole, Stinger, Patient, Risk, Drug identification number, Blister, Infection, Natural product, Health Canada, Red, Herpes simplex, Heart, Pregnancy, Allergy, Face, Xeroderma, Pharmacy, Blurred vision, Weakness, Tropical ulcer, Viral, Itch, Anaphylaxis, Dexamethasone, Hearing, Kidney, Liver, Fungal infection, Headache, Sleep, Mouth, Skin, Safety, Common, Injection, Tremor, Yohimbine, Erythromycin, Tablet, Dizziness, Tuberculosis, Swelling, Immune system, Triamcinolone, Heart rate, Blood pressure, DIN, Neomycin, Connective tissue, Central nervous system, Diabetes, Liver disease, Anxiety, Inflammation, Sale, Stomach, NPN, Irritation, Nausea, Throat, Health, Dietary supplement, Vaccine

Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from Yang Sheng Health Food Ltd. and two G&R Ginseng Trading Ltd. locations in Richmond, B.C.
  • These products are labelled to contain prescription drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Consult a health care professional if you have used any of these products and have health concerns.

Public advisory - Unauthorized health products seized from T&T Supermarket in North York, Ontario, as they may pose serious health risks

Retrieved on: 
Thursday, July 27, 2023
Elasticity, DIN, Hair, Pregnancy, Diabetes, Mouth, Allergy, Prescription drug, Gland, Atrophoderma, Xeroderma, Pharmacy, Blurred vision, Infection, Sheppard, Eye, Weakness, Health Canada, Tropical ulcer, Viral, Unit, Inflammation, Sale, Rash, Dexamethasone, Plasma protein binding, Itch, NPN, Patient, Tuberculosis, Swelling, Risk, Drug identification number, Triamcinolone, Natural product, Fungal infection, Throat, Health, Red, Herpes simplex, Skin, Safety, Common, Dietary supplement, Cosmetics

Health Canada is warning consumers about unauthorized Japanese-labelled drugs that it seized from T&T Supermarket in North York (Unit 1115, 1800 Sheppard Ave. E,), Ontario.

Key Points: 
  • Health Canada is warning consumers about unauthorized Japanese-labelled drugs that it seized from T&T Supermarket in North York (Unit 1115, 1800 Sheppard Ave. E,), Ontario.
  • The products are labelled to contain prescription drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Consult a health care professional if you have used any of these products and have health concerns.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

PositiveSingles, Dating Site Dedicated to STD Positive Individuals, Launches Unique Feature for Members to Share Custom Events for a More Personalized Dating Experience

Retrieved on: 
Tuesday, April 4, 2023
HIV/AIDS, IPhone, STI, Infection, Herpes simplex, Android, PositiveSingles, STD, Attitude, ID, Judgement, HPV, Vertically transmitted infection, Diagnosis, Online shopping

The organization aims to create the largest community for STD positive people who can be there for each other and help each other in need.

Key Points: 
  • The organization aims to create the largest community for STD positive people who can be there for each other and help each other in need.
  • The "My Event" feature offered by PositiveSingles enables members to efficiently prepare and publicize upcoming events to fellow community members.
  • Hence, with this revolutionary new feature, PositiveSingles opens a new avenue in the dating experience.
  • For a long time, PositiveSingles has been making its mark in the dating business by having high quality members.

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Retrieved on: 
Wednesday, January 4, 2023
Death, World Health Organization, CE, European Centre for Disease Prevention and Control, Environment, HPV, Growth, COVID-19, Diagnosis, Control, Risk, Nature, Cervical cancer, Union, Hepatitis B, Multimedia, Monkeypox, Therapy, Herpes simplex, Infection, Degenerative disease, Woman, Vaccine, Malaria, EU

LONDON, Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.

Key Points: 
  • The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
  • These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe.
  • Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.
  • T-Cell testing can be particularly effective in the management and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.